FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES... - 03 December 2022 04:39

MIAMI, Dec. 3, 2022 /PRNewswire-AsiaNet/ -- -- The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for...

  Sirolimus Coated Balloon in BTK Treatment makes a bold presenc... - 03 December 2022 00:53

TAMPA, Fla., Dec. 2, 2022 /PRNewswire-AsiaNet/ -- VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease. Concept Medical Inc. [https://www.conceptmedical.com/] hosted a lunch symposium titled 'Sirolimus Coated Ba...

  Encore Medical Education announces publication of the Official... - 01 December 2022 18:45

SAN ANTONIO, Dec. 1, 2022 /PRNewswire-AsiaNet/ -- - Best of SABCS(R) News Highlights coverage will provide daily expert video summaries along with original presentation slides of the most significant breast cancer trials for oncologists worldwide. Encore Medical Education [http://www.encor...

  New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio - 01 December 2022 11:00

DUBLIN, Dec. 1, 2022 /PRNewswire-AsiaNet/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Cosmo Bio. This is a non-exclusive license agreement granting Japan's Cosmo Bio access to the ERS CRISPR/Cas9 patent portfolio. ERS, co-founded by Dr. Emmanuelle C...

  LUCIDITY phase 3 topline data presented at CTAD for HMTM – the... - 01 December 2022 09:13

ABERDEEN, Scotland and SINGAPORE, Nov. 30, 2022 /PRNewswire-AsiaNet/ -- - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Diseas...

  Menarini Group Presents Updated Results from Pivotal Phase 3 E... - 01 December 2022 03:52

FLORENCE, Italy, November, 30, 2022, /PRNewswire-AsiaNet/-- • Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors • Elacestrant side effects were manageable...

  Global alliance of heart patient organizations unveils new Glo... - 30 November 2022 19:00

GALWAY, Ireland, Nov. 30, 2022 /PRNewswire-AsiaNet/-- The Global Heart Hub has today launched its Global Cholesterol Action Plan[https://invisiblenation.globalhearthub.org/] to reduce the impact of unhealthy cholesterol levels . Presented at their annual UNITE Summit , the Action Plan follows and bui...

  TargEDys and SymbioPharm enter an exclusive partnership to lau... - 29 November 2022 21:15

PARIS, Nov. 29, 2022 /PRNewswire-AsiaNet/ -- TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife(R) Satylia(R) in Germany. The novel dietary supplement based on the next-generation probiotic Hafnia alvei HA4597 will be available from...

  Probiotic strain SNZ 1969(R) helps manage IBS-D & IBS-C sympto... - 29 November 2022 19:06

HYDERABAD, India, Nov. 29, 2022 /PRNewswire-Asianet/ -- Latest study shows Sanzyme Biologics's Bacillus coagulans SNZ 1969(R)(Weizmannia coagulans SNZ 1969), a natural spore forming probiotic strain over five decades of use and more than 30 human studies across age groups found to be effective in m...

  COLOTECT - Non-invasive Colorectal Cancer Screening Test has b... - 25 November 2022 21:58

BANGKOK, Thailand, Nov. 25, 2022 /Xinhua-AsiaNet/-- COLOTECT is a non-invasive colorectal cancer (CRC) self-sampling test that can detect the methylation status of exfoliated cell genes in the intestine, help screen for colorectal cancer and precancerous lesions risk, and detect bowel cancer risk e...